Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc. has demonstrated positive momentum, with a revenue beat in 3Q25 and a raised mid-point guidance, reflecting the company’s commitment to enhancing its Light Adjustable Lens (LAL) volumes through targeted engagement initiatives. The anticipation of sustained double-digit growth is supported by a growing installed base of Light Delivery Devices (LDD) and increased utilization, which positions the company favorably in the medical technology landscape. Furthermore, the management’s projection of improved gross margins, now estimated between 76-77%, underscores the potential for enhanced profitability amid strategic operational focus.

Bears say

RxSight Inc. is experiencing a decline in both monthly utilization rates and revenue, with a reported 14% year-over-year decrease, indicating potential challenges in customer adoption and demand for its light adjustable lenses (LALs). In the second quarter of 2025, the company placed only 25 light delivery devices (LDDs), which represents a substantial 68% drop year-over-year and a 38% decrease quarter-over-quarter, significantly underperforming expectations. Additionally, risks related to limited market adoption due to the necessity of additional capital equipment, disappointing commercial execution, and the potential for increased competition in the intraocular lens market further contribute to a negative outlook on RxSight's stock.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.